196 related articles for article (PubMed ID: 11190904)
21. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
22. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
23. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
24. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities].
Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S
Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105
[TBL] [Abstract][Full Text] [Related]
26. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
27. Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.
Silver PJ; Broughton R; Bouthillier J; Quinn TA; Wallace AM; Weishaar RE
Thromb Res; 1998 Aug; 91(3):143-50. PubMed ID: 9733158
[TBL] [Abstract][Full Text] [Related]
28. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
29. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
30. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
31. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant and antiprotease activities of aprosulate sodium, a new synthetic polyanion, in human plasma and purified systems.
Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):773-9. PubMed ID: 7865684
[TBL] [Abstract][Full Text] [Related]
33. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
34. Comparison between a low molecular weight and standard heparin for anticoagulation during extracorporeal CO2 removal in the dog.
Reber G; Schweizer A; de Moerloose P; Sinclair ME; Bouvier CA; Gardaz JP
Thromb Res; 1988 Jan; 49(2):157-68. PubMed ID: 3129814
[TBL] [Abstract][Full Text] [Related]
35. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
36. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase.
Linhardt RJ; Grant A; Cooney CL; Langer R
J Biol Chem; 1982 Jul; 257(13):7310-3. PubMed ID: 7085627
[TBL] [Abstract][Full Text] [Related]
37. Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin.
Olson G; Jeske W; Iqbal O; Krupa E; Farooqui A; Siddiqui F; Hoppensteadt D; Kouta A; Fareed J
Clin Appl Thromb Hemost; 2023; 29():10760296231163251. PubMed ID: 36908199
[No Abstract] [Full Text] [Related]
38. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
[TBL] [Abstract][Full Text] [Related]
39. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
[TBL] [Abstract][Full Text] [Related]
40. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
Alban S; Lühn S; Schiemann S
Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]